Search

Your search keyword '"Angiogenesis inhibitors -- Physiological aspects"' showing total 79 results
Start Over Descriptor "Angiogenesis inhibitors -- Physiological aspects"
79 results on '"Angiogenesis inhibitors -- Physiological aspects"'

1. Anaplerotic nutrient stress drives synergy of angiogenesis inhibitors with therapeutics targeting tumor metabolism (Updated October 19, 2023)

Subjects
Tumors -- Physiological aspects, Cancer -- Care and treatment, Angiogenesis inhibitors -- Physiological aspects, Business, Health, Health care industry
Abstract

2023 NOV 7 (NewsRx) -- By a News Reporter-Staff News Editor at Cancer Weekly -- According to news reporting based on a preprint abstract, our journalists obtained the following quote [...]

Published
2023

2. Researchers at Affiliated Hospital of Xuzhou Medical University Have Published New Study Findings on Gene Therapy (PEDF is an antifibrosis factor that inhibits the activation of fibroblasts in a bleomycin-induced pulmonary fibrosis rat model)

Subjects
Glycoproteins -- Physiological aspects -- Health aspects, Pulmonary fibrosis -- Development and progression -- Care and treatment, Angiogenesis inhibitors -- Physiological aspects, Health
Abstract

2022 MAY 14 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Research findings on gene therapy are discussed in a new report. According [...]

Published
2022

3. Anaplerotic nutrient stress drives synergy of angiogenesis inhibitors with therapeutics targeting tumor metabolism

Subjects
Tumors -- Physiological aspects, Neovascularization -- Physiological aspects, Cancer -- Care and treatment, Angiogenesis inhibitors -- Physiological aspects, Business, Health, Health care industry
Abstract

2023 MAY 23 (NewsRx) -- By a News Reporter-Staff News Editor at Cancer Weekly -- According to news reporting based on a preprint abstract, our journalists obtained the following quote [...]

Published
2023

4. Switching Patterns Among Neovascular Age-Related Macular Degeneration: Genentech's Vabysmo Rising, Regeneron's Eylea & Genentech's Off-Label Avastin Remain Strong, According to Spherix Global Insights

Subjects
Biological products industry -- Product discontinuation, Macular degeneration -- Physiological aspects, Angiogenesis inhibitors -- Physiological aspects, General interest, News, opinion and commentary, Vabysmo (Medication) -- Product discontinuation
Abstract

EXTON: The switch landscape represents an active segment of the market where brands have the opportunity to capture share. Spherix's RealWorld Dynamix service takes a unique approach to the typical [...]

Published
2023

5. Switching Patterns Among Neovascular Age-Related Macular Degeneration: Genentech's Vabysmo Rising, Regeneron's Eylea and Genentech's Off-Label Avastin Remain Strong, According to Spherix Global Insights

Subjects
Biological products industry -- Product discontinuation, Macular degeneration -- Physiological aspects, Angiogenesis inhibitors -- Physiological aspects, Company marketing practices, Business, News, opinion and commentary, Eylea (Medication) -- Product discontinuation -- Marketing, Vabysmo (Medication) -- Marketing -- Product discontinuation, Avastin (Medication) -- Product discontinuation -- Marketing
Abstract

Despite the availability of new agents, established brands remain market leaders within the switch segment. EXTON, Pa., Jan. 18, 2023 /PRNewswire/ -- The switch landscape represents an active segment of [...]

Published
2023

6. Studies Conducted at College of Fisheries on Aquaculture Nutrition Recently Published [Effects of Genistein on Lipid Metabolism, Antioxidant Activity, and Immunity of Common Carp (Cyprinus carpio L.) Fed with High-Carbohydrate and High-Fat Diets]

Subjects
Fish-culture -- Physiological aspects, Fishes -- Physiological aspects, Nutrition -- Physiological aspects, Aquaculture industry -- Physiological aspects, Antioxidants -- Physiological aspects, Aquaculture -- Physiological aspects, Angiogenesis inhibitors -- Physiological aspects, Isoflavones -- Physiological aspects, Carp -- Physiological aspects, Diet -- Physiological aspects, Biological sciences, Health
Abstract

2023 APR 25 (NewsRx) -- By a News Reporter-Staff News Editor at Life Science Weekly -- Data detailed on aquaculture nutrition have been presented. According to news reporting from the [...]

Published
2023

7. Isoflavones isolated from red clover (Trifolium pratense) inhibit smooth muscle contraction of the isolated rat prostate gland

Author

Brandli, A., Simpson, J.S., and Ventura, S.

Subjects
Sheep -- Physiological aspects, Mimosaceae -- Physiological aspects, Esters -- Physiological aspects, Myosin -- Physiological aspects, Noradrenaline -- Physiological aspects, Legumes -- Physiological aspects, Muscle proteins -- Physiological aspects, Liquid chromatography -- Physiological aspects, Questions and answers -- Physiological aspects, Resveratrol -- Physiological aspects, Animal experimentation -- Physiological aspects, Fatty acids -- Physiological aspects, Angiogenesis inhibitors -- Physiological aspects, Isoflavones -- Physiological aspects, Beans -- Physiological aspects, Biological sciences, Health, Science and technology
Abstract

ABSTRACT This study investigated whether red clover contains any bioactive constituents which may affect contractility of rat prostatic smooth muscle in an attempt to determine whether its medicinal use in [...]

Published
2010
Full Text
View/download PDF

8. Blocking the Wnt pathway, a unifying mechanism for an angiogenic inhibitor in the serine proteinase inhibitor family

Author

Zhang, Bin, Abreu, Jose G., Zhou, Kevin, Chen, Ying, Hu, Yang, Zhou, Ti, He, Xi, and Ma, Jian-xing

Subjects
Angiogenesis inhibitors -- Physiological aspects, Angiogenesis inhibitors -- Genetic aspects, Cellular signal transduction -- Physiological aspects, Cellular signal transduction -- Genetic aspects, Wnt proteins -- Physiological aspects, Wnt proteins -- Genetic aspects, Science and technology
Abstract

The Wnt pathway regulates multiple biological and pathological processes including angiogenesis and inflammation. Here we identified a unique inhibitor of the Wnt pathway, SERPINA3K, a serine proteinase inhibitor with anti-inflammatory and angiogenic activities. SERPINA3K blocked the Wnt pathway activation induced by a Wnt ligand and by diabetes. Coprecipitation and ligand binding assay showed that SERPINA3K binds to low-density lipoprotein receptor-like protein 6 (LRP6) with a Kd of 10 nM, in the range of its physiological concentration in the retina. Under the same conditions, SERPINA3K did not bind to the frizzled (Fz) receptor or low-density lipoprotein receptor. Further, SERPINA3K bound to LRP6 at the extracellular domain and blocked its dimerization with the Fz receptor induced by a Wnt ligand. The antagonizing activity of SERPINA3K to LRP6 was further confirmed by Xenopus axis duplication assay. These results suggest that S ERPINA3 K is a high-affinity, endogenous antagonist of LRP6. The blockade of Wnt signaling may represent a unifying mechanism for the anti-inflammatory and antiangiogenic effects of SERPINA3K. angiogenesis | [beta]-catenin | lipoprotein receptor-related protein 6 | vascular endothelial growth factor doi/ 10.1073/pnas.0906764107

Published
2010

9. New Breast Cancer Data Have Been Reported by Researchers at University of Vienna (The Impacts of Genistein and Daidzein on Estrogen Conjugations in Human Breast Cancer Cells: A Targeted Metabolomics Approach)

Subjects
Isoflavones -- Physiological aspects, Angiogenesis inhibitors -- Physiological aspects, Cancer prevention -- Physiological aspects, Women's health -- Physiological aspects, Cancer cells -- Physiological aspects, Cancer research -- Physiological aspects, Estrogens -- Physiological aspects, Breast cancer -- Physiological aspects, Phenols (Class of compounds) -- Physiological aspects, Health, Women's issues/gender studies, University of Vienna
Abstract

2017 NOV 9 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- Investigators publish new report on Oncology - Breast Cancer. According to news reporting originating [...]

Published
2017

10. University of Geneva Researchers Further Understanding of Cancer (Celecoxib Analogues for Cancer Treatment: An Update on OSU-03012 and 2,5-Dimethyl-Celecoxib)

Subjects
Oncology, Experimental -- Physiological aspects, Prostaglandins -- Physiological aspects, Cancer -- Care and treatment -- Research, Angiogenesis inhibitors -- Physiological aspects, Enzymes -- Physiological aspects, COX-2 inhibitors -- Physiological aspects, Celecoxib -- Physiological aspects, Health
Abstract

2021 AUG 9 (NewsRx) -- By a News Reporter-Staff News Editor at Clinical Oncology Week -- New research on cancer is the subject of a new report. According to news [...]

Published
2021

12. Investigators at Gachon University Zero in on Hepatomas (Celecoxib-mediated activation of endoplasmic reticulum stress induces de novo ceramide biosynthesis and apoptosis in hepatoma HepG2 cells mobilization)

Subjects
Apoptosis -- Physiological aspects, Physical fitness -- Physiological aspects, Angiogenesis inhibitors -- Physiological aspects, Hepatocellular carcinoma -- Physiological aspects, Liver diseases -- Physiological aspects, Celecoxib -- Physiological aspects, Ceramides -- Physiological aspects, Health
Abstract

2017 APR 15 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- New research on Liver Diseases and Conditions - Hepatomas is the subject [...]

Published
2017

13. Treatment of patients with metastatic renal cell cancer: a RAND appropriateness panel

Author

Halbert, Ronald J., Figlin, Robert A., Atkins, Michael B., Bernal, Myriam, Hutson, Thomas E., Uzzo, Robert G., Bukowski, Ronald M., Khan, Khuda Dad, Wood, Christopher G., and Dubois, Robert W.

Subjects
Carcinoma, Renal cell -- Care and treatment, Carcinoma, Renal cell -- Research, Metastasis -- Care and treatment, Angiogenesis inhibitors -- Analysis, Angiogenesis inhibitors -- Physiological aspects, Practice guidelines (Medicine) -- Evaluation, Health
Published
2006

14. Intravitreal Bevacizumab for the Management of Choroidal Neovascularization in Age-related Macular Degeneration

Author

Bashshur, Ziad F., Bazarbachi, Ali, Schakal, Alexandre, Haddad, Zeina A., Haibi, Christelle P. El, and Noureddin, Baha' N.

Subjects
Angiogenesis inhibitors -- Physiological aspects, Ophthalmology -- Physiological aspects, Neovascularization -- Physiological aspects, Macular degeneration -- Physiological aspects, Health
Abstract

To link to full-text access for this article, visit this link: http://dx.doi.org/10.1016/j.ajo.2006.02.037 Byline: Ziad F. Bashshur (a), Ali Bazarbachi (b), Alexandre Schakal (c), Zeina A. Haddad (a), Christelle P. El Haibi (a), Baha' N. Noureddin (a) Abstract: To investigate the efficacy and safety of intravitreal bevacizumab for managing choroidal neovascularization (CNV) due to age-related macular degeneration (AMD). Author Affiliation: (a) Department of Ophthalmology, American University of Beirut, Beirut, Lebanon (b) Department of Internal Medicine, American University of Beirut, Beirut, Lebanon (c) Department of Ophthalmology, Hotel Dieu de France (St Joseph University), Beirut, Lebanon Article History: Accepted 24 February 2006 Article Note: (footnote) See accompanying Editorial on page 141.

Published
2006

15. Studies from Chulalongkorn University Provide New Data on Apoptosis [Genistein Modulated Lipid Metabolism, Hepatic Ppar Gamma, and Adiponectin Expression In Bilateral Ovariectomized Rats With Nonalcoholic Steatohepatitis (Nash)]

Subjects
Education grants -- Physiological aspects, Angiogenesis inhibitors -- Physiological aspects, Isoflavones -- Physiological aspects, Endowments -- Physiological aspects, Estrogen -- Physiological aspects, Apoptosis -- Physiological aspects, Health
Abstract

2021 MAR 5 (NewsRx) -- By a News Reporter-Staff News Editor at Health & Medicine Week -- Researchers detail new data in Cellular Physiology - Apoptosis. According to news reporting [...]

Published
2021

16. Researchers from Chulalongkorn University Describe Findings in Apoptosis [Genistein Modulated Lipid Metabolism, Hepatic PPARg, and Adiponectin Expression in Bilateral Ovariectomized Rats with Nonalcoholic Steatohepatitis (NASH)]

Subjects
Biochemistry -- Physiological aspects, Angiogenesis inhibitors -- Physiological aspects, Isoflavones -- Physiological aspects, Estrogen -- Physiological aspects, Apoptosis -- Physiological aspects, Health
Abstract

2021 JAN 15 (NewsRx) -- By a News Reporter-Staff News Editor at Health & Medicine Week -- Current study results on Cellular Physiology - Apoptosis have been published. According to [...]

Published
2021

17. Reports on Age-Related Macular Degeneration from Hedi Rais Institute of Ophthalmology Provide New Insights (Effect of Risk Alleles in CFH, C3, and VEGFA on the Response to Intravitreal Bevacizumab in Tunisian Patients with Neovascular ...)

Subjects
Macular degeneration -- Care and treatment -- Physiological aspects, Alleles -- Physiological aspects, Physical fitness -- Physiological aspects, Angiogenesis inhibitors -- Physiological aspects, Vascular endothelial growth factor -- Physiological aspects, Eye diseases -- Care and treatment -- Physiological aspects, Ophthalmology -- Physiological aspects, Health
Abstract

2016 JUN 4 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Data detailed on Eye Diseases and Conditions have been presented. According to [...]

Published
2016

18. New Findings Reported from M. Etminan and Co-Authors Describe Advances in Age-Related Macular Degeneration (Risk of Myocardial Infarction and Stroke With Single or Repeated Doses of Intravitreal Bevacizumab in Age-Related Macular Degeneration)

Subjects
Macular degeneration -- Risk factors -- Physiological aspects, Physical fitness -- Physiological aspects, Angiogenesis inhibitors -- Physiological aspects, Heart attack -- Risk factors -- Physiological aspects, Eye diseases -- Risk factors -- Physiological aspects, Health
Abstract

2016 APR 2 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Investigators discuss new findings in Eye Diseases and Conditions. According to news [...]

Published
2016

19. More questions have been raised as to why eye drug Lucentis continues to be used instead of the cheaper Avastin to treat wet age-related macular degeneration in the UK

Subjects
Novartis AG, Macular degeneration -- Physiological aspects, Angiogenesis inhibitors -- Physiological aspects, Ophthalmic agents -- Physiological aspects, Pharmaceutical industry -- Physiological aspects, Business, Health care industry, Business, international, General Medical Council, Lucentis (Medication), Avastin (Medication)
Abstract

More questions have been raised as to why eye drug Lucentis continues to be used instead of the cheaper Avastin to treat wet age-related macular degeneration in the UK. According [...]

Published
2015

20. Intravitreal Bevacizumab (Avastin) for Neovascular Age-related Macular Degeneration: A Short-term Study

Author

Chen, Christine Y., Wong, Tien Y., and Heriot, Wilson J.

Subjects
Angiogenesis inhibitors -- Physiological aspects, Eye diseases -- Physiological aspects, Macular degeneration -- Physiological aspects, Health
Abstract

To link to full-text access for this article, visit this link: http://dx.doi.org/10.1016/j.ajo.2006.10.004 Byline: Christine Y. Chen (a)(b), Tien Y. Wong (a)(b), Wilson J. Heriot (c) Abstract: To report the short-term study of intravitreal bevacizumab (Avastin) in the treatment of neovascular age-related macular degeneration (AMD). Author Affiliation: (a) Center for Eye Research Australia, University of Melbourne, Melbourne, Victoria, Australia (b) Royal Victorian Eye and Ear Hospital, East Melbourne, Victoria, Australia (c) Eye Surgery Associates, Cabrini Medical Centre, Malvern, Victoria, Australia Article History: Accepted 2 October 2006

Published
2007

21. Data on Proinsulin Reported by A. Lewicka and Colleagues (Effects of genistein on insulin pathway-related genes in mouse differentiated myoblast C2C12 cell line: evidence for two independent modes of action)

Subjects
Genetic research -- Physiological aspects, Isoflavones -- Physiological aspects, Proteins -- Physiological aspects, House mouse -- Physiological aspects, Genes -- Physiological aspects, Angiogenesis inhibitors -- Physiological aspects, Insulin -- Physiological aspects, Peptides, Carbohydrate metabolism, Anopheles, Editors, Biological sciences, Health
Abstract

2019 FEB 12 (NewsRx) -- By a News Reporter-Staff News Editor at Life Science Weekly -- Investigators discuss new findings in Peptide Proteins - Proinsulin. According to news reporting out [...]

Published
2019

22. Ophthotech Announces Results from Third Phase 3 Trial of Fovista[R] in Wet Age-Related Macular Degeneration

Subjects
Clinical trials -- Physiological aspects, Macular degeneration -- Care and treatment -- Physiological aspects, Angiogenesis inhibitors -- Physiological aspects, Vascular endothelial growth factor -- Physiological aspects, Business, Business, international, Eylea (Medication) -- Product development, Avastin (Medication) -- Product development
Abstract

NEW YORK -- Ophthotech Corporation (Nasdaq:OPHT) today announced that the pre-specified primary endpoint of mean change in visual acuity at 12 months was not achieved in its Phase 3 clinical [...]

Published
2017

23. Castration-resistant prostate cancer cell growth impeded by Endostatin

Subjects
Angiogenesis inhibitors -- Physiological aspects, Prostate cancer -- Care and treatment -- Physiological aspects, News, opinion and commentary, Sports and fitness
Abstract

Byline: Jeff Hansen Joo Hyoung Lee, Ph.D., left, and Selvarangan Ponnazhagen, Ph.D.Failure of hormone deprivation therapy, which is used to slow prostate cancer in patients, leads to castration-resistant prostate cancer, [...]

Published
2017

24. Bevacizumab vs Ranibizumab for Age-Related Macular Degeneration: Early Results of a Prospective Double-Masked, Randomized Clinical Trial

Subjects
Angiogenesis inhibitors -- Physiological aspects, Macular degeneration -- Physiological aspects, Clinical trials -- Physiological aspects, Health
Abstract

To link to full-text access for this article, visit this link: http://dx.doi.org/10.1016/j.ajo.2009.07.009 Byline: Manju L. Subramanian (a)(b), Steven Ness (a)(b), Gelareh Abedi (a)(b), Ednan Ahmed (a)(b), Mary Daly (a)(b), Edward Feinberg (a)(b), Sumit Bhatia (a)(b), Payal Patel (b), Maileah Nguyen (a), Antoun Houranieh (a) Abstract: To report early outcomes of a prospective, double-masked, controlled trial comparing bevacizumab (Avastin; Genentech Inc, South San Francisco, California, USA) to ranibizumab (Lucentis; Genentech Inc) for the treatment of age-related macular degeneration. Author Affiliation: (a) Veterans Affairs Boston Healthcare System, Jamaica Plain, Massachusetts (b) Department of Ophthalmology, Boston University School of Medicine, Boston, Massachusetts Article History: Accepted 13 July 2009

Published
2009

25. Quantification of Error in Optical Coherence Tomography Central Macular Thickness Measurement in Wet Age-related Macular Degeneration

Author

Ghazi, Nicola G., Kirk, Tyler, Allam, Souha, and Yan, Guofen

Subjects
Angiogenesis inhibitors -- Measurement, Angiogenesis inhibitors -- Physiological aspects, Macular degeneration -- Measurement, Macular degeneration -- Physiological aspects, Tomography -- Measurement, Tomography -- Physiological aspects, Health
Abstract

To link to full-text access for this article, visit this link: http://dx.doi.org/10.1016/j.ajo.2009.02.017 Byline: Nicola G. Ghazi (a), Tyler Kirk (a), Souha Allam (a), Guofen Yan (b) Abstract: To assess error indicators encountered during optical coherence tomography (OCT) automated retinal thickness measurement (RTM) in neovascular age-related macular degeneration (NVAMD) before and after bevacizumab (Avastin; Genentech Inc, South San Francisco, California, USA) treatment. Author Affiliation: (a) Department of Ophthalmology, The University of Virginia Health System, Charlottesville, Virginia (b) Department of Biostatistics, the University of Virginia Health System, Charlottesville, Virginia Article History: Accepted 10 February 2009

Published
2009

26. Intravitreal Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration: The Second Year of a Prospective Study

Author

Bashshur, Ziad F., Haddad, Zeina A., Schakal, Alexandre R., Jaafar, Rola F., Saad, Alain, and Noureddin, Baha' N.

Subjects
Angiogenesis inhibitors -- Physiological aspects, Ophthalmology -- Physiological aspects, Macular degeneration -- Drug therapy, Macular degeneration -- Physiological aspects, Health
Abstract

To link to full-text access for this article, visit this link: http://dx.doi.org/10.1016/j.ajo.2009.02.006 Byline: Ziad F. Bashshur (a), Zeina A. Haddad (a), Alexandre R. Schakal (b), Rola F. Jaafar (a), Alain Saad (b), Baha' N. Noureddin (a) Abstract: To demonstrate the efficacy of intravitreal bevacizumab for treatment of neovascular age-related macular degeneration (AMD). Author Affiliation: (a) Department of Ophthalmology, American University of Beirut, Beirut, Lebanon (b) Department of Ophthalmology, Hotel Dieu de France, St Joseph University, Beirut, Lebanon Article History: Accepted 3 February 2009 Article Note: (footnote) See accompanying Editorial on page 1.

Published
2009

27. Intravitreal Bevacizumab Therapy for Neovascular Age-related Macular Degeneration with Large Submacular Hemorrhage

Author

Stifter, Eva, Michels, Stephan, Prager, Franz, Georgopoulos, Michael, Polak, Kaija, Hirn, Cornelia, and Schmidt-Erfurth, Ursula

Subjects
Angiogenesis inhibitors -- Physiological aspects, Eye diseases -- Care and treatment, Eye diseases -- Physiological aspects, Macular degeneration -- Care and treatment, Macular degeneration -- Physiological aspects, Health
Abstract

To link to full-text access for this article, visit this link: http://dx.doi.org/10.1016/j.ajo.2007.07.034 Byline: Eva Stifter, Stephan Michels, Franz Prager, Michael Georgopoulos, Kaija Polak, Cornelia Hirn, Ursula Schmidt-Erfurth Abstract: To evaluate functional and anatomic effects of intravitreal bevacizumab (Avastin; Roche Pharma, Vienna, Austria) in patients with neovascular age-related macular degeneration (AMD) with large submacular hemorrhages. Author Affiliation: Department of Ophthalmology, Medical University of Vienna, Austria. Article History: Accepted 26 July 2007

Published
2007

28. The economic implications of the use of anti-vascular endothelial growth factor drugs in age-related macular degeneration

Author

Azad, Rajvardhan, Chandra, Parijat, and Gupta, Ritesh

Subjects
Endothelial growth factors -- Physiological aspects, Eye diseases -- Drug therapy -- Physiological aspects, Macular degeneration -- Drug therapy -- Physiological aspects, Cancer -- Care and treatment, Angiogenesis inhibitors -- Physiological aspects, Health, Avastin (Medication)
Abstract

Byline: Rajvardhan. Azad, Parijat. Chandra, Ritesh. Gupta Age-related macular degeneration (ARMD) is the most common cause for visual impairment in the elderly in western countries. Recently several anti-vascular endothelial growth [...]

Published
2007

29. Lenalidomide Data in Multiple Myeloma Patients Demonstrate Impressive Survival Benefit

Subjects
Angiogenesis inhibitors -- Dosage and administration, Angiogenesis inhibitors -- Physiological aspects, Dexamethasone -- Dosage and administration, Multiple myeloma -- Patient outcomes, Multiple myeloma -- Care and treatment, Multiple myeloma -- Drug therapy
Abstract

Findings from a phase III study by the Eastern Cooperative Oncology Group (ECOG 4A03), presented at the recent American Society of Clinical Oncology (ASCO) meeting held June 2-5 in Chicago, [...]

Published
2007

30. Ophthotech Completes Patient Recruitment in Phase 3 Trial of Fovista[R] Anti-PDGF Therapy in Combination with Eylea[R] or Avastin[R] in Wet Age-Related Macular Degeneration

Subjects
Novartis Pharma AG -- Product development -- Recruiting, Clinical trials -- Physiological aspects, Macular degeneration -- Care and treatment -- Physiological aspects, Angiogenesis inhibitors -- Physiological aspects, Pharmaceutical industry -- Product development -- Physiological aspects, Platelet-derived growth factor -- Physiological aspects, Industry hiring, Business, Business, international, Eylea (Medication), Avastin (Medication)
Abstract

- $30 Million Milestone Triggered by Reaching Final Enrollment Goal in the Third Phase 3 Trial in the Fovista ([R] ) Program - NEW YORK -- Ophthotech Corporation (Nasdaq: OPHT) [...]

Published
2016

31. LONG-TERM BENEFITS OF AGE-RELATED MACULAR DEGENERATION TREATMENTS

Subjects
United States. National Institutes of Health, Macular degeneration -- Drug therapy -- Physiological aspects, Angiogenesis inhibitors -- Physiological aspects, News, opinion and commentary, Lucentis (Medication), Avastin (Medication)
Abstract

BETHESDA, MD -- The following information was released by the National Institutes of Health (NIH): At a Glance Researchers examined the 5-year outcomes of using the drugs Avastin and Lucentis [...]

Published
2016

32. Ophthotech Completes Patient Recruitment of the First Phase 3 Pivotal Trial of Fovista[R] Anti-PDGF Therapy in Combination with Lucentis[R] in Wet Age-Related Macular Degeneration Program

Subjects
Clinical trials -- Physiological aspects, Macular degeneration -- Care and treatment -- Physiological aspects, Angiogenesis inhibitors -- Physiological aspects, Platelet-derived growth factor -- Physiological aspects, Industry hiring, Business, Business, international, Eylea (Medication) -- Product development, Lucentis (Medication) -- Product development, Avastin (Medication) -- Product development
Abstract

- Conference Call and Webcast Today, May 11, 2015 at 5:00 p.m. ET - NEW YORK -- Ophthotech Corporation (Nasdaq: OPHT) today announced the completion of patient recruitment of its [...]

Published
2015

33. Avastin (Macular Edema and Macular Degeneration) - Forecast and Market Analysis to 2023

Subjects
Macular degeneration -- Physiological aspects, Angiogenesis inhibitors -- Physiological aspects, Vascular endothelial growth factor -- Physiological aspects, Edema -- Physiological aspects, Business, Business, international, Avastin (Medication)
Abstract

M2 PRESSWIRE-March 24, 2015-: Avastin (Macular Edema and Macular Degeneration) - Forecast and Market Analysis to 2023 (C)1994-2015 M2 COMMUNICATIONS RDATE:24032015 Dublin - Research and Markets (http://www.researchandmarkets.com/research/cnvt75/avastin_macular) has announced the [...]

Published
2015

34. Research and Markets: Avastin (Macular Edema and Macular Degeneration) - Forecast and Market Analysis to 2023

Subjects
Macular degeneration -- Physiological aspects, Angiogenesis inhibitors -- Physiological aspects, Vascular endothelial growth factor -- Physiological aspects, Edema -- Physiological aspects, Business, Business, international, Avastin (Medication)
Abstract

DUBLIN -- Research and Markets (http://www.researchandmarkets.com/research/rkw3lf/avastin_macular) has announced the addition of the 'Avastin (Macular Edema and Macular Degeneration) - Forecast and Market Analysis to 2023' report to their offering. Currently [...]

Published
2015

35. Avastin (Macular Edema and Macular Degeneration) - Forecast and Market Analysis to 2023

Subjects
Genentech Inc., Macular degeneration -- Physiological aspects, Angiogenesis inhibitors -- Physiological aspects, Vascular endothelial growth factor -- Physiological aspects, Edema -- Physiological aspects, General interest, News, opinion and commentary, Avastin (Medication)
Abstract

Mar 24, 2015 (M2 PRESSWIRE via COMTEX) -- Research and Markets (http://www.researchandmarkets.com/research/cnvt75/avastin_macular) has announced the addition of the 'Avastin (Macular Edema and Macular Degeneration) - Forecast and Market Analysis to [...]

Published
2015

36. Increased Scrutiny by EU5 Health Authorities Will Encourage Use of Off-label Avastin and Emerging Biosimilars in the European Wet Age-Related Macular Degeneration Market

Subjects
Vascular endothelial growth factor -- Physiological aspects, Macular degeneration -- Physiological aspects, Angiogenesis inhibitors -- Physiological aspects, Business, News, opinion and commentary, Avastin (Medication)
Abstract

Novel Therapies Demonstrating Evidence of Superior Head-to-Head Efficacy Will Expand the Role of Adjunct Therapy, According to Findings from Decision Resources Group BURLINGTON, Mass., Nov. 4, 2014 /PRNewswire/ -- Decision [...]

Published
2014

37. Genistein

Subjects
Angiogenesis inhibitors -- Physiological aspects, Isoflavones -- Physiological aspects
Abstract

Nutraceutical: Genistein Indication: Bone density Source: Ann Intern Med, June 19, 2007;146(12):839-47. Research: To assess the effects of genistein on bone metabolism in nearly 400 osteopenic postmenopausal women, researchers conducted [...]

Published
2007

38. Injecting new life into AMD: recent treatments for age-related macular degeneration not only halt the disease but improve vision. Which one is right for your patient?

Author

Ajamian, Paul C.

Subjects
Avastin (Medication), Lucentis (Medication), Angiogenesis inhibitors -- Physiological aspects, Neovascularization -- Physiological aspects, Eye diseases -- Drug therapy, Eye diseases -- Physiological aspects, Macular degeneration -- Drug therapy, Macular degeneration -- Physiological aspects
Abstract

Q I have a patient with age-related macular degeneration (AMD) who said his retina specialist wants to do a series of injections in his eye over the next six months. [...]

Published
2007

39. Researchers at Hebrew University Medical Center Release New Data on Age-Related Macular Degeneration (Bevacizumab treatment for neovascular age-related macular degeneration in the setting of a clinic: 'real life' long-term outcome)

Subjects
Macular degeneration -- Drug therapy -- Physiological aspects, Angiogenesis inhibitors -- Physiological aspects, Medical centers -- Physiological aspects, Eye diseases -- Drug therapy -- Physiological aspects, Health
Abstract

2016 FEB 26 (NewsRx) -- By a News Reporter-Staff News Editor at Health & Medicine Week -- Investigators discuss new findings in Eye Diseases and Conditions. According to news reporting [...]

Published
2016

40. Reports on Glioblastomas from NorLux Neuro-Oncology Laboratory Provide New Insights (Bevacizumab treatment induces metabolic adaptation toward anaerobic metabolism in glioblastomas)

Subjects
Angiogenesis inhibitors -- Physiological aspects, Glucose metabolism -- Physiological aspects, Biological sciences, Health
Abstract

2015 OCT 27 (NewsRx) -- By a News Reporter-Staff News Editor at Life Science Weekly -- Investigators publish new report on Oncology. According to news reporting originating in Strassen, Luxembourg, [...]

Published
2015

41. Ophthotech Completes Patient Recruitment of the First Phase 3 Pivotal Trial of Fovista[R] Anti-PDGF Therapy in Combination with Lucentis[R] in Wet Age-Related Macular Degeneration Program

Subjects
Clinical trials -- Physiological aspects, Macular degeneration -- Care and treatment -- Physiological aspects, Angiogenesis inhibitors -- Physiological aspects, Platelet-derived growth factor -- Physiological aspects, Industry hiring, Health, Eylea (Medication) -- Product development, Lucentis (Medication) -- Product development, Avastin (Medication) -- Product development
Abstract

By a News Reporter-Staff News Editor at Clinical Trials Week -- Ophthotech Corporation (Nasdaq: OPHT) announced the completion of patient recruitment of its first Phase 3 trial of Fovista® in [...]

Published
2015

42. Recent Studies from University of the Pacific Add New Data to Age-Related Macular Degeneration (Intravitreal Aflibercept after Bilateral Bevacizumab-Induced Iritis)

Subjects
Macular degeneration -- Physiological aspects, Angiogenesis inhibitors -- Physiological aspects, Uveitis -- Physiological aspects, Biotechnology industry, Pharmaceuticals and cosmetics industries, University of the Pacific
Abstract

By a News Reporter-Staff News Editor at Biotech Week -- Investigators discuss new findings in Eye Diseases and Conditions. According to news originating from Forest Grove, Oregon, by NewsRx correspondents, [...]

Published
2015

43. Data on Physiology Detailed by Researchers at Nagasaki University (Genistein improves spatial learning and memory in male rats with elevated glucose level during memory consolidation)

Subjects
Isoflavones -- Physiological aspects, Angiogenesis inhibitors -- Physiological aspects, Blood glucose -- Physiological aspects, Biological sciences, Health, Nagasaki University
Abstract

By a News Reporter-Staff News Editor at Life Science Weekly -- Investigators publish new report on Life Science Research. According to news reporting from Nagasaki, Japan, by NewsRx journalists, research [...]

Published
2015

44. After 18 Months On the U.S. Market, Regeneron's Eylea Captures One-Fifth of First-Line Intravitreal Pharmacotherapy Share Among Wet Age-Related Macular Degeneration (AMD) Patients

Subjects
Endothelial growth factors -- Physiological aspects, Macular degeneration -- Drug therapy -- Physiological aspects, Angiogenesis inhibitors -- Physiological aspects, Business, News, opinion and commentary, Eylea (Medication), Avastin (Medication)
Abstract

Regardless of First-Line Therapy Choice, Treatment Typically Occurs Within Same Month As Wet AMD Diagnosis, According to a New Report from BioTrends Research Group EXTON, Pa., July 10, 2013 /PRNewswire/ [...]

Published
2013

45. Two-year results confirm strong efficacy of two drugs in treatment of age-related macular degeneration

Subjects
Macular degeneration -- Drug therapy -- Care and treatment -- Physiological aspects, Angiogenesis inhibitors -- Physiological aspects, Business, Chemicals, plastics and rubber industries, Lucentis (Medication), Avastin (Medication)
Abstract

The results of the second year of the Comparison of Age-related macular degeneration Treatment Trials (CATT) indicate that bevacizumab (Avastin) is equivalent to ranibizumab (Lucentis) in the treatment of wet [...]

Published
2012

46. Macular degeneration drugs compared

Subjects
Drugs -- Physiological aspects, Macular degeneration -- Drug therapy -- Physiological aspects, Angiogenesis inhibitors -- Physiological aspects, General interest, News, opinion and commentary, Lucentis (Medication), Avastin (Medication)
Abstract

BETHESDA, Md., April 30 (UPI) -- Two drugs used for age-related macular degeneration were 'highly effective' but Avastin was more frequently used in a head-to-head test, U.S. researchers said. Dr. [...]

Published
2012

47. AVASTIN AND LUCENTIS ARE EQUIVALENT IN TREATING AGE-RELATED MACULAR DEGENERATION

Subjects
Medical research -- Physiological aspects, Medicine, Experimental -- Physiological aspects, Eye diseases -- Physiological aspects, Macular degeneration -- Physiological aspects, Angiogenesis inhibitors -- Physiological aspects, News, opinion and commentary, Lucentis (Medication), Avastin (Medication)
Abstract

BETHESDA, Md. -- The following information was released by the National Institutes of Health: At two years, Avastin (bevacizumab) and Lucentis (ranibizumab injection), two widely used drugs to treat age-related [...]

Published
2012

48. Avastin and Lucentis are equivalent in treating age-related macular degeneration

Subjects
Macular degeneration -- Physiological aspects, Angiogenesis inhibitors -- Physiological aspects, Health
Abstract

At two years, Avastin (bevacizumab) and Lucentis (ranibizumab injection), two widely used drugs to treat age-related macular degeneration (AMD), improve vision when administered monthly or on an as needed basis, [...]

Published
2012

49. LCQ18: Drugs for wet age-related macular degeneration treatment

Subjects
Macular degeneration -- Drug therapy -- Physiological aspects, Cancer -- Care and treatment, Angiogenesis inhibitors -- Physiological aspects, Government, Lucentis (Medication), Avastin (Medication)
Abstract

Hong Kong, Jul. 13 -- Hong Kong SAR Government issued the following news release: Following is a question by the Hon Ronny Tong and a written reply by the Acting [...]

Published
2011

50. Avastin found effective against macular degeneration

Subjects
Genentech Inc., Biotechnology industry -- Physiological aspects, Macular degeneration -- Physiological aspects, Angiogenesis inhibitors -- Physiological aspects, Business, Chemicals, plastics and rubber industries, Lucentis (Medication), Avastin (Medication)
Abstract

The anti-cancer drug Avastin is as effective in fighting macular degeneration as Lucentis, which, however is 40 times more expensive than the cancer fighting medicine, according to results of clinical [...]

Published
2011

Catalog

Books, media, physical & digital resources
See catalog results